Mereo Biopharma Group Stock Today

MREO Stock  USD 3.98  0.27  6.35%   

Performance

10 of 100

 
Weak
 
Strong
OK

Odds Of Distress

Less than 9

 
High
 
Low
Low
Mereo BioPharma is selling at 3.98 as of the 20th of June 2024; that is -6.35 percent decrease since the beginning of the trading day. The stock's open price was 4.25. Mereo BioPharma has less than a 9 % chance of experiencing financial distress in the next few years and had a ok performance during the last 90 days. Equity ratings for Mereo BioPharma Group are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 21st of April 2024 and ending today, the 20th of June 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
24th of April 2019
Category
Healthcare
Classification
Health Care
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom. The company has 152.8 M outstanding shares of which 2.4 M shares are now shorted by private and institutional investors with about 2.72 trading days to cover. More on Mereo BioPharma Group

Moving together with Mereo Stock

  0.64ESPR Esperion TherapeuticsPairCorr

Moving against Mereo Stock

  0.63DMTK DermTechPairCorr
  0.48ACRV Acrivon TherapeuticsPairCorr
  0.44BMY Bristol Myers SquibbPairCorr
  0.42INMB INmune BioPairCorr
  0.4MYMD MyMD PharmaceuticalsPairCorr
  0.39AKAN Akanda CorpPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Mereo Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEODenise ScotsKnight
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities14.3 M9.5 M
Way Up
Slightly volatile
Non Current Liabilities Total6.2 M6.5 M
Notably Down
Slightly volatile
Total Assets70.1 M66.5 M
Notably Up
Slightly volatile
Total Current Assets64.2 M63.8 M
Slightly Up
Slightly volatile
Mereo BioPharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Mereo BioPharma's financial leverage. It provides some insight into what part of Mereo BioPharma's total assets is financed by creditors.
Liquidity
Mereo BioPharma Group currently holds 5.95 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. Mereo BioPharma Group has a current ratio of 7.76, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Mereo BioPharma's use of debt, we should always consider it together with its cash and equity.

Depreciation

699,621
Mereo BioPharma Group (MREO) is traded on NASDAQ Exchange in USA. It is located in One Cavendish Place, London, United Kingdom, W1G 0QF and employs 33 people. Mereo BioPharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 608.16 M. Mereo BioPharma Group conducts business under Biotechnology sector and is part of Health Care industry. The entity has 152.8 M outstanding shares of which 2.4 M shares are now shorted by private and institutional investors with about 2.72 trading days to cover. Mereo BioPharma Group currently holds about 94.3 M in cash with (21.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.81.
Check Mereo BioPharma Probability Of Bankruptcy
Ownership Allocation
Mereo BioPharma Group maintains a total of 152.8 Million outstanding shares. Over half of Mereo BioPharma's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Mereo Ownership Details

Mereo Stock Institutional Holders

InstituionRecorded OnShares
Goldman Sachs Group Inc2024-03-31
2.2 M
Millennium Management Llc2024-03-31
2.2 M
Renaissance Technologies Corp2024-03-31
1.7 M
Susquehanna International Group, Llp2024-03-31
1.6 M
Morgan Stanley - Brokerage Accounts2024-03-31
1.4 M
T. Rowe Price Associates, Inc.2024-03-31
992 K
Integral Health Asset Management, Llc2024-03-31
950 K
Abrdn Plc2024-03-31
817.3 K
Neos Investment Management, Llc2024-03-31
623.4 K
Rubric Capital Management Lp2024-03-31
13.6 M
Adage Capital Partners Gp Llc2024-03-31
9.3 M
View Mereo BioPharma Diagnostics

Mereo BioPharma Historical Income Statement

At this time, Mereo BioPharma's Interest Income is very stable compared to the past year. As of the 20th of June 2024, Interest Expense is likely to grow to about 2.9 M, while Tax Provision is likely to drop (558.6 K). View More Fundamentals

Mereo Stock Against Markets

Mereo BioPharma Corporate Management

Christine CPAChief OfficerProfile
Bo KaraSenior CMCProfile
Fiona BorHead PropertyProfile
Jackie ParkinTherapy EndocrinologyProfile
MBBS MDCoFounder StrategyProfile
John LewickiChief OfficerProfile

Additional Information and Resources on Investing in Mereo Stock

When determining whether Mereo BioPharma Group offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mereo BioPharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mereo Biopharma Group Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mereo Biopharma Group Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.15)
Revenue Per Share
0.074
Return On Assets
(0.21)
Return On Equity
(0.56)
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.